We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2010 by Rudolf Foundation Clinic.
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01174407
First Posted: August 3, 2010
Last Update Posted: August 3, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Rudolf Foundation Clinic
  Purpose
The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration. The aim is to asses a difference in expression rates of these factors on AMD-patients and a healthy control group.

Condition Intervention
Age-Related Macular Degeneration Other: cd 35, cd21, cd55

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Is CD35, CD21 and CD55 Associated With Exudative Age-related Macular Degeneration

Resource links provided by NLM:


Further study details as provided by Rudolf Foundation Clinic:

Primary Outcome Measures:
  • determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration [ Time Frame: 1 day ]

Secondary Outcome Measures:
  • expression rates of on AMD-patients and a healthy control group [ Time Frame: 1 year ]

Estimated Enrollment: 120
Study Start Date: September 2008
Estimated Study Completion Date: August 2010
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
cd35 Other: cd 35, cd21, cd55
Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
patients with exudative age-related macular degeneration, over 55
Criteria

Inclusion Criteria:

  • Man and women over 18 years old
  • Filled out informed consent
  • Diagnosis of non-exudative/ exudative age related macular degeneneration

Exclusion Criteria:

  • Inherited retinal diseases
  • Other acquired retinal/ macular
  • Missing informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01174407


Locations
Austria
Rudolf Foundation Clinic
Vienna, Austria, 1030
Sponsors and Collaborators
Rudolf Foundation Clinic
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Prof. Dr. Susanne Binder, Rudolf Foundation Clinic
ClinicalTrials.gov Identifier: NCT01174407     History of Changes
Other Study ID Numbers: EK08010-VK
First Submitted: November 19, 2008
First Posted: August 3, 2010
Last Update Posted: August 3, 2010
Last Verified: August 2010

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases